Treatment of @entity951 with XXXX : the significance of intrinsic sympathomimetic activity of beta blockers.

@entity1169 @entity1 @entity5394 @entity7690 @entity951 @entity2142
Although all beta blockers have been found to be effective in the symptomatic relief of @entity951 , the importance of intrinsic sympathomimetic activity (ISA) has not been studied extensively. In a randomized, double-blind study, we administered equipotent doses of @entity1169 (10, 20, and 40 mg four times a day) and @entity7690 (2.5, 5, and 10 mg four times a day), a beta blocker with significant ISA, to 52 @entity1 with @entity951 . Both agents were found to be effective in the treatment of @entity951 . At peak dose, @entity1169 reduced the number of @entity951 @entity5394 weeks from 29.29 +/- 4.79 to 18.0 +/- 4.4 (p = 0.021) (a 39% reduction) and increased the exercise tolerance on the treadmill from 7.55 +/- 0.67 METS to 9.36 +/- 0.58 (p = 0.002). @entity7690 decreased the number of @entity2142 @entity5394 weeks from 16.48 +/- 2.63 to 8.65 +/- 2.46 (p = 0.0027) (a 48% reduction) and increased exercise tolerance from 7.95 +/- 0.56 METS to 9.40 +/- 0.57 (p = 0.0245). At the end of the maximum tolerated exercise, @entity1169 decreased the heart rate from 110.00 +/- 3.41 to 99.71 +/- 3.74 (p = 0.0015). @entity7690 also decreased the heart rate at the maximum tolerated exercise from 113.59 +/- 3.24 to 108.12 +/- 3.16 (p = 0.0102). At rest, however, @entity1169 induced a more pronounced (p = 0.0066) decrease in heart rate (from 69.00 +/- 1.85 to 61.50 +/- 1.99; p = 0.0018), whereas @entity7690 did not significantly affect the resting heart rate (65.37 +/- 1.47 to 65.5 +/- 1.44; p = 0.9392). In addition @entity1169 decreased echocardiographically determined ejection fraction from 0.57 +/- 0.02 to 0.15 +/- 0.01 (p = 0.04) and increased the left ventricular end-diastolic volume from 71.8 +/- 3.2 to 92.2 +/- 1.9 ml (p = 0.003), whereas @entity7690 did not affect the ejection fraction and caused a less pronounced (p = 0.03) increase in end-diastolic volume (from 70.8 +/- 1.8 to 80.2 +/- 2.8; p = 0.02). The data indicate that both @entity1169 and @entity7690 are effective in the treatment of @entity951 and that @entity7690 decreases the resting heart rate and ejection fraction and increases the left ventricular end-diastolic volume to a lesser extent than @entity1169 .
